Cytogenetic remissions induced by interferon α and imatinib mesylate are immunologically distinct in...
Cytogenetic remissions induced by interferon α and imatinib mesylate are immunologically distinct in chronic myeloid leukemia
About this item
Full title
Author / Creator
Publisher
Tokyo: Springer
Journal title
Language
English
Formats
Publication information
Publisher
Tokyo: Springer
Subjects
More information
Scope and Contents
Contents
We compared immunologic parameters of chronic myeloid leukemia (CML) patients in cytogenetic remission receiving imatinib mesylate (STI) treatment, CML patients receiving interferon alpha (IFN-alpha), and healthy volunteers. Each group comprised 14 subjects. Median treatment dosages and durations were 6 x 10(6) IU/week and 174 months, respectively,...
Alternative Titles
Full title
Cytogenetic remissions induced by interferon α and imatinib mesylate are immunologically distinct in chronic myeloid leukemia
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_68489237
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_68489237
Other Identifiers
ISSN
0925-5710
E-ISSN
1865-3774
DOI
10.1007/BF03006921
